Financial Performance Overview
Ambalal Sarabhai Enterprises Limited reported strong consolidated financial results for FY 2025-26 with revenue of ₹202.27 crores (up from ₹196.19 crores in FY25) and net profit of ₹17.80 crores, representing a 261% increase from ₹4.93 crores in the previous year. Profit before tax stood at ₹19.33 crores compared to ₹11.83 crores in FY25. The Group recognized an exceptional item of ₹(81.99) lakhs related to the statutory impact of new labour codes effective November 2025.
Regulatory Compliance & AGM Details
The Company submitted a revised Annual Report for FY 2025-26 to BSE Limited on July 8, 2026, noting certain inadvertent errors in the originally submitted report. The 48th Annual General Meeting will be held virtually on July 30, 2026, with e-voting scheduled for July 27-29, 2026. Key AGM agenda items include reappointment of executive directors Mr. Kartikeya V. Sarabhai (Executive Chairman), Mr. Mohal K. Sarabhai (Managing Director), and Ms. Chaula M. Shastri (Whole-time Director), along with approval of ₹10 crore loans each to three subsidiary companies.
Subsidiary Operations & Performance
The Group operates through eight subsidiaries in pharmaceuticals and electronics: Synbiotics Limited (revenue ₹210.42 million, profit ₹15.71 million), Systronics India Limited (revenue ₹941.95 million, profit ₹54.91 million), Asence Pharma Private Limited (revenue ₹763.86 million, loss ₹12.91 million), and others. The Group also has investments in two joint ventures - Vovantis Laboratories (33.34% holding, share of profit ₹7.14 million) and Cosara Diagnostics (50% holding, share of loss ₹4.97 million) - and one associate company Haryana Containers Limited (45.45% holding, share of profit ₹2.05 million).
Audit & Governance Matters
Statutory auditors Sorab S. Engineer & Co. issued an unmodified opinion on the consolidated financial statements, with uncertain tax positions identified as a key audit matter. The Board consists of 10 directors (5 independent, 3 executive, 2 nominee directors) with all mandatory committees established. The Company confirmed no fund diversions, crypto transactions, benami properties, or wilful default status during the year.
Shareholding & Corporate Structure
Promoters hold 31.36% of equity shares with public holding at 68.64%. Dematerialized shares represent 83.98% of total equity. The consolidated balance sheet shows total assets of ₹281.13 crores, total equity of ₹158.36 crores, and borrowings of ₹51.65 crores (current ₹33.99 crores, non-current ₹17.65 crores). No dividend was recommended for the year.